Evidence map›Paper›PMID 31931507›Full record

ReviewPediatric research2020

How to introduce MSC-based therapy for the developing lung safely into clinical care?

Mario Rüdiger, Haresh Kirpalani, Robin Steinhorn, Jonathan M Davis, Bernard Thebaud

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pediatric research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Update in Pediatrics 2020.American journal of respiratory and critical care medicine · 2021
    Article
  5. Present and Future of Bronchopulmonary Dysplasia.Journal of clinical medicine · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mario RüdigerSaxony Center for Feto-Neonatal Health; Department for Neonatology and Pediatric Intensive Care Medicine, Universitätskinderklinik, Universitätsklinikum Dresden, Center for Regenerative Therapies (CRTD), TU Dresden, Dresden, Germany. Mario.ruediger@uniklinikum-dresden.de.
Haresh KirpalaniDivision of Neonatology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA.
Robin SteinhornChildren's National Hospital and George Washington University, Washington, DC, USA.
Jonathan M DavisDepartment of Pediatrics, The Floating Hospital for Children at Tufts Medical Center and the Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, USA.
Bernard ThebaudDepartment of Pediatrics, Division of Neonatology, Children's Hospital of Eastern Ontario (CHEO) and CHEO Research Institute, Sinclair Center for Regenerative Medicine, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.

Funding

CIHR FDN-143316
6 · The paper itself

Abstract

Extreme prematurity is associated with an increased risk to develop bronchopulmonary dysplasia (BPD). Severe BPD is associated with a significant long-term burden for the affected infant, families and society. Currently there are limited prevention and treatment options. Regenerative approaches using mesenchymal stromal cells (MSC) are associated with promising benefits in animal experiments. First clinical studies, using MSC in humans, suggest safety. To accelerate the process of bench to bed-side development of MSC-based therapies, a global and collaborative approach is needed that includes all key stakeholders. Results of a workshop that was held during the Pediatric Academic Societies meeting in 2019 are summarized. A roadmap is provided discussing next steps of bringing MSC-based interventions into clinical practice.

Indexed as

AnimalsBronchopulmonary DysplasiaCell- and Tissue-Based TherapyClinical Trials as TopicHumansInfant, NewbornInfant, PrematureInternational CooperationLungMesenchymal Stem CellsMesenchymal Stem Cell TransplantationPediatricsRegenerationResearch Design

Identifiers

PMID31931507

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.